Akili, a pioneer in therapeutic digital prescription medicine, has successfully closed its C-Series medicine trial with $55 million in funding. This funding follows a successful trial, including the study, development and testing of a new digital medicine called AKL-T01. This Akili flagship product was aimed at treating a type of cognitive disorder: attention deficit/hyperactivity disorder (ADHD). Once approved and released commercially, it would be the first stand-alone digital therapeutic drug for ADHD. The company’s other product under development and research, AKL-T02, will treat autism spectrum disorder (ASD) or what is simply known as autism.

Autism refers to another type of cognitive disorder, particularly in children, which makes it difficult for them to interact socially. Repetitive behavior and underdeveloped speech and verbal communication make them vulnerable in society. The reason behind autism could be genetic as well as environmental influence.

The above news has brought a new ray of hope for an autism patient where there is no specific traditional medicine available for his cure. This new development has the potential to treat this disorder, probably more effectively.

This funding will also help promote products in development for the treatment of multiple sclerosis (MS) and depression. After US Food and Drug Administration (FDA) approval, it will be released commercially for patients. According to Akili, AKL-T01 would be a standalone treatment for ADHD.

The company’s founder and CEO, Eddie Martucci, is very pleased with the response from investors and appreciated the funding. He said this funding indicates people’s faith in their company’s potential in digital medicine and growth. According to him, the company will continue to grow and offer innovative solutions in the redefined healthcare sector.

Akini Interactive is a company that believes in transforming healthcare through its digital therapeutic medicine that addresses neurocognitive disorders. He believes in targeting a specific cognitive area or nerve that has been suppressed by dysfunction. The treatment includes, interestingly, not just any pill, but personalized action video games for patients to play.

Video games are designed by neuroscientists and artists designed with algorithms to treat a cognitive disorder like depression. According to the company, the highly interactive and engaging games provide a therapeutic experience to patients that truly benefits them. Through high-end therapeutic interactive video games, specific brain regions could become functional that have been suppressed by the disorder, improving the patient’s condition. There would be second-by-second monitoring of the patient’s cognitive response and data available for any improvements in the patient’s condition.

AKL-T01 if approved by the FDA and then it would certainly indicate the acceptance of new healthcare solutions for patients. It has the ability to transform the entire healthcare process and system for years to come. This funding will boost the confidence of other investors, who plan to invest in or join in digital medicine research and development in the future, and those patients looking for new areas to treat disorders such as autism will be more than happy to read this article. positive news